Genetic Markers Predict Primary Non-Response and Durable Response To Anti-TNF Biologic Therapies in Crohn's Disease.

Autor:	Barber GE; Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Yajnik V; Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Khalili H; Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Giallourakis C; Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Garber J; Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Xavier R; Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Ananthakrishnan AN; Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Jazyk:	angličtina
Zdroj:	The American journal of gastroenterology [Am J Gastroenterol] 2016 Dec; Vol. 111 (12), pp. 1816-1822. Date of Electronic Publication: 2016 Sep 06.
DOI:	10.1038/ajg.2016.408
Abstrakt:	Objectives: One-fifth of patients with Crohn's disease (CD) are primary non-responders to anti-tumor necrosis factor (anti-TNF) therapy, and an estimated 10-15% will fail therapy annually. Little is known about the genetics of response to anti-TNF therapy. The aim of our study was to identify genetic factors associated with primary non-response (PNR) and loss of response to anti-TNFs in CD. Methods: From a prospective registry, we characterized the response of 427 CD patients to their first anti-TNF therapy. Patients were designated as achieving primary response, durable response, and non-durable response based on clinical, endoscopic, and radiologic criteria. Genotyping was performed on the Illumina Immunochip. Separate genetic scores based on presence of predictive genetic alleles were calculated for PNR and durable response and performance of clinical and genetics models were compared. Results: From 359 patients, 36 were adjudged to have PNR (10%), 200 had durable response, and 74 had non-durable response. PNRs had longer disease duration and were more likely to be smokers. Fifteen risk alleles were associated with PNR. Patients with PNR had a significantly higher genetic risk score (GRS) (P =8 × 10 -12 ). A combined clinical-genetic model more accurately predicted PNR when compared with a clinical only model (0.93 vs. 0.70, P <0.001). Sixteen distinct single nucleotide polymorphisms predicted durable response with a higher GRS (P =7 × 10 -13 ). The GRSs for PNR and durable response were not mutually correlated, suggesting distinct mechanisms. Conclusions: Genetic risk alleles can predict primary non-response and durable response to anti-TNF therapy in CD. Competing Interests: Grant Barber – no conflict of interest exists Vijay Yajnik – no conflict of interest exists Hamed Khalili – Received consulting fees from Abbvie, Inc. Cosmas Giallourakis – no conflict of interest exists John Garber - no conflict of interest exists Ramnik Xavier - no conflict of interest exists Ashwin Ananthakrishnan - Scientific advisory board for Cubist pharmaceuticals, Abbvie,Exact Sciences
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu